phase III clinical study
Canhelp Genomics Partners With Mirxes Singapore to Offer Tumor Origin Identification Testing
The firms will make the Canhelp-Origin tumor identification test available for patients with cancers of unknown origin in some Southeast Asian countries.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
The firm is building a case for clinical utility of its gene expression test for cancer of unknown primary following a successful validation study.
Gene Expression Assay Shows Ability to Guide Targeted Treatment for Patients With Occult Cancers
Premium
Patients with cancers of unknown primary had more treatment options and better outcomes when care was informed by a 90-gene expression assay.
Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial
The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.